Sign up Australia
Proactive Investors - Run By Investors For Investors

Immuron receives R&D tax refund

Immuron receives R&D tax refund

Immuron (ASX:IMC) has received $1,469,763 in a cash refund from a Research & Development programs during 2015 in the form of tax concessions.

The Incentive refund is a tax concession for Australian biotechnology companies to fund ongoing research and development pipelines and advance promising programs.

Immuron’s marketed product, Travelan, is for the prevention of travellers’ diarrhoea, while its lead product candidate IMM-124E is in Phase 2b clinical trials for NASH and ASH.

The company focuses on commercialising oral immunotherapeutics for the treatment of a many gut mediated diseases.


Proactive Investors is a global leader reporting financial news, media, research and hosts events for listed emerging growth companies and investors across four continents.

View full IMC profile

Immuron Timeline

Newswire
May 27 2016

Related Articles

cancer cells
January 25 2017
The US-based, London-listed healthcare group topped expectations with its latest results and analysts are tipping it for more success this year
Blood testing
February 14 2017
Identifying cancer cells early is a key part of combatting the disease, and ANGLE's Parsortix device looks to be developing into a key ally.
newspaper with word cancer magnified
January 30 2017
The start of 2017 has seen some good trial results for its skin cancer treatment, as well as a collaboration deal that will accelerate the development of its lung cancer drug

© Proactive Investors 2017

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use